Obesity最新文献

{"title":"Association of serum 25-hydroxyvitamin D with sarcopenic obesity risk: a longitudinal observational study from the UK Biobank","authors":"Qian Xu,&nbsp;Fan Bu,&nbsp;Zi-Tong Song,&nbsp;Kuan Li,&nbsp;Chen Fang,&nbsp;Yuan Luo,&nbsp;Lei Zhang,&nbsp;Yu-Fang Pei","doi":"10.1002/oby.24286","DOIUrl":"10.1002/oby.24286","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aims to examine the association of serum 25-hydroxyvitamin D (25[OH]D) concentration with the risk of sarcopenic obesity (SO) incidence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We used the longitudinal observational data from the UK Biobank cohort to evaluate the association between serum 25(OH)D concentration and the risk of SO incidence (<i>N</i> = 46,535). Cox proportional hazards models were used to estimate the hazard ratios (HRs) and 95% CI between serum 25(OH)D concentration and risk of SO incidence by sex.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>During the median follow-up of 8.74 (IQR 6.70–11.06) years, there were 1086 incident SO cases. After multivariable adjustment, compared with the lowest quartile group, the HRs (95% CI) for the second, third, and fourth quartile of 25(OH)D concentration in female individuals were 0.66 (95% CI: 0.53–0.82), 0.53 (95% CI: 0.41–0.67), and 0.43 (95%: 0.33–0.55), respectively (<i>p</i>_trend &lt; 0.001). Similarly, in male individuals, the HRs (95% CI) for the second, third, and fourth quartile of 25(OH)D concentration were 0.86 (95% CI: 0.66–1.10), 0.68 (95% CI: 0.56–0.92), and 0.40 (95% CI: 0.29–0.54), respectively (<i>p</i>_trend &lt;0.001). A nonlinear association between serum 25(OH)D concentration and risk of SO incidence was observed in female (<i>p</i>_nonlinear = 0.043) and male (<i>p</i>_nonlinear = 0.008) individuals using restricted cubic spline analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Higher serum 25(OH)D concentration was significantly associated with a lower risk of SO incidence in a dose–response relationship.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 6","pages":"1136-1144"},"PeriodicalIF":4.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bidirectional associations between adiposity and mental health: a prospective cohort study of the UK Biobank","authors":"Meng Lv,&nbsp;Ying Li,&nbsp;Zihan Guo,&nbsp;Lu Ma,&nbsp;Lei Zhang","doi":"10.1002/oby.24296","DOIUrl":"10.1002/oby.24296","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to examine the bidirectional associations between indicators of adiposity and mental health.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Using longitudinal data from 60,319 UK Biobank participants, we explored the bidirectional associations between mental health (including neuroticism, recent depressive symptoms, probable depression status, stress, mania, life satisfaction, and happiness) and adiposity indicators (including BMI, waist circumference, body fat percentage, and different obesity types).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The multivariate logistic regressions and mixed-effects models revealed the following: 1) BMI and general obesity were bidirectionally associated with recent depressive symptoms, having probable depression status, experiencing at least one type of stress (especially stress from serious illness, injury, or assault to oneself or financial difficulties), and life satisfaction (especially health satisfaction and financial situation satisfaction); 2) waist circumference and abdominal obesity were bidirectionally associated with recent depressive symptoms and financial situation satisfaction; and 3) body fat percentage and high body fat percentage were bidirectionally associated with recent depressive symptoms, experiencing stress from financial difficulties, health satisfaction, and financial situation satisfaction.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The bidirectional associations between specific indicators of adiposity and mental health depend on the types of adiposity.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 6","pages":"1195-1206"},"PeriodicalIF":4.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24296","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144035301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential weight-loss responses of APOA2 genotype carriers to low-carbohydrate and low-fat diets: the DIETFITS trial","authors":"Chao-Qiang Lai,&nbsp;Laurence D. Parnell,&nbsp;Sai Krupa Das,&nbsp;Christopher D. Gardner,&nbsp;José M. Ordovás","doi":"10.1002/oby.24288","DOIUrl":"10.1002/oby.24288","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to determine whether <i>APOA2</i> genotypes and saturated fatty acid (SAT) intake affect weight-loss response to healthy low-carbohydrate (HLC) and healthy low-fat (HLF) diets.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This is a secondary analysis of the Diet Intervention Examining The Factors Interacting with Treatment Success (DIETFITS) study, a 12-month randomized clinical trial of HLC or HLF diets in 609 adults aged 18 to 50 years with BMI values between 28 and 40 kg/m². The current study examined 3-, 6-, and 12-month weight loss in participants with different <i>APOA2</i> genotypes (TT vs. C allele carriers, CT + CC) at variant rs5082 who met the SAT intake criterion of ≥22 g/day for an HLC diet and &lt; 22 g/day for an HLF diet at all three study time points.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Participants with the TT <i>APOA2</i> genotype lost significantly more weight consistently on an HLC diet than on an HLF diet at 3, 6, and 12 months, whereas C allele carriers lost more weight only at 3 months and not at 6 or 12 months. <i>APOA2</i> genotype-by-SAT intake interaction affecting weight loss was observed only at 12 months. Among participants who did not consistently meet the SAT intake criterion, there were no significant weight-loss differences among <i>APOA2</i> genotypes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study highlights the importance of evaluating genotype–diet interactions in weight-loss trials to better inform precision nutrition interventions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Clinical Trial Registration: NCT01826591</h3>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 6","pages":"1048-1057"},"PeriodicalIF":4.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24288","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144046886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of protein supplementation on body composition after bariatric surgery: a systematic review and meta-analysis of randomized controlled trials","authors":"Mahsa Ranjbar,&nbsp;Maryam Fallah,&nbsp;Kurosh Djafarian,&nbsp;Hamed Mohammadi,&nbsp;Gholamreza Mohammadi Farsani,&nbsp;Sakineh Shab-Bidar","doi":"10.1002/oby.24283","DOIUrl":"10.1002/oby.24283","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>We aimed to explore the effect of protein supplementation on anthropometric measures and body composition in patients after metabolic bariatric surgery (MBS).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We performed a systematic search up to January 2024 including randomized controlled trials investigating the effects of protein or amino acid supplementation on the body composition of patients who underwent MBS. The overall effect was presented as the weighted mean difference (WMD) at a 95% CI.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Ten trials were included in this meta-analysis. Our results indicate that there was a statistically greater change in weight (WMD, −1.31 kg, 95% CI: −1.93 to −0.69, <i>p</i> &lt; 0.001; Grading of Recommendations Assessment, Development, and Evaluation [GRADE] = moderate), muscle mass (WMD, 1.33 kg, 95% CI: 0.1 to 2.57, <i>p</i> = 0.035; GRADE = low), fat-free mass (WMD, 1.74 kg, 95% CI: 0.46 to 3.01, <i>p</i> = 0.01; GRADE = low), and fat mass (WMD, −3.91 kg, 95% CI: −4.10 to −0.59, <i>p</i> = 0.01; GRADE = low) in the protein group compared to the control group. However, protein supplementation did not significantly change BMI and lean body mass.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Based on moderate- to low-certainty evidence, our findings suggest that although protein supplementation may improve weight and some body composition metrics, it does not influence overall BMI and lean body mass. More research is needed to recommend protein supplementation after MBS.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 6","pages":"1027-1036"},"PeriodicalIF":4.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The NLRP3 inhibitor NT-0796 enhances and sustains GLP-1R agonist-mediated weight loss in a murine diet-induced obesity model","authors":"Peter Thornton,&nbsp;Valérie Reader,&nbsp;Zsofia Digby,&nbsp;John Doedens,&nbsp;Nicola Lindsay,&nbsp;Nicholas Clarke,&nbsp;Alan P. Watt","doi":"10.1002/oby.24305","DOIUrl":"10.1002/oby.24305","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>In order to investigate whether a central nervous system penetrant anti-inflammatory could augment or sustain obesity treatment with semaglutide (Wegovy), a glucagon-like peptide-1 receptor (GLP-1R) agonist, we tested two hypotheses in models of diet-induced obesity (DIO): 1) a centrally penetrant NLPR3 inhibitor, NT-0796, drives enhanced weight loss when combined with low-dose semaglutide, compared to monotherapy; and 2) NT-0796 monotherapy sustains weight loss induced by semaglutide.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Mice fed a standard high-fat or a polyunsaturated fatty acid diet served as models of DIO and were dosed with low-dose semaglutide, NT-0796, or combinations. Body weight, food intake, peripheral inflammatory markers, and hypothalamic glial fibrillary acidic protein expression were assessed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Combined dosing of NT-0796 with semaglutide drove greater weight loss than either monotherapy alone, and this effect was enhanced in mice consuming the polyunsaturated fatty acid diet. In addition, NT-0796 sharply limited weight regain following cessation of semaglutide therapy and normalized markers of both peripheral inflammation and hypothalamic astrogliosis to a far greater extent than either semaglutide or calorie restriction.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Alleviation of obesity-associated inflammation via NLRP3 inhibition 1) constitutes an effective weight-loss strategy as monotherapy in mice with DIO, 2) augments the weight-loss efficacy of a subtherapeutic dose of semaglutide, and 3) blocks recovery of lost weight following cessation of semaglutide.</p>\u0000 \u0000 <div>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 7","pages":"1309-1321"},"PeriodicalIF":4.2,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24305","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Grandmaternal perinatal serum polychlorinated biphenyls and prevalence of obesity in adult daughters and granddaughters","authors":"Barbara A. Cohn,&nbsp;Piera M. Cirillo,&nbsp;Michele A. La Merrill,&nbsp;Caitlin C. Murphy,&nbsp;Xin Hu,&nbsp;Nickilou Y. Krigbaum","doi":"10.1002/oby.24284","DOIUrl":"10.1002/oby.24284","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>We investigated in utero exposure to polychlorinated biphenyl (PCB) 138, PCB 153, and PCB 180 and obesity at reproductive age in a three-generation human cohort, i.e., the Child Health and Development Studies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We used logistic models to estimate associations of PCBs in grandmothers' (F0) archived perinatal serum with obesity in daughters (F1) at age 30 years and granddaughters (F2) at age 26 years, accounting for family clustering (<i>n</i> = 258 triads). In order to reflect mixture exposures, we modeled PCBs as a ratio of the sum of PCB 138 + PCB 180 to PCB 153 (i.e., “PCB ratio”).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>An increase in the PCB ratio from the first to the third tertile corresponded to a 1.73 (95% CI: 1.06–2.82) increase in the odds of F1 obesity and a 1.96 (95% CI: 1.12–3.42) increase in the odds of F2 obesity. The association with F2 obesity differed by F0 BMI (<i>p</i> value for interaction = 0.08). F1 obesity was also associated with F2 obesity (odds ratio, 4.12, 95% CI: 1.95–8.72).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Grandmothers' perinatal serum levels of mixtures of PCBs may have triggered a multigenerational cycle of obesity in daughters and granddaughters. Resultant obesity among women of reproductive age could further perpetuate obesity in subsequent generations.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 6","pages":"1165-1175"},"PeriodicalIF":4.2,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24284","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceptions of anti-obesity medications among people with obesity and healthcare providers in the US: Findings from the OBSERVE Study","authors":"Lee M. Kaplan,&nbsp;Kimberly Gudzune,&nbsp;Jamy Ard,&nbsp;Rekha Kumar,&nbsp;Nadia N. Ahmad,&nbsp;Hong Kan,&nbsp;Tracy J. Sims,&nbsp;Jiat Ling Poon,&nbsp;Kristen King-Concialdi,&nbsp;Kathleen Beusterien,&nbsp;Sheila Drakeley,&nbsp;Julia P. Dunn,&nbsp;Scott Kahan,&nbsp;the OBSERVE Study","doi":"10.1002/oby.24290","DOIUrl":"10.1002/oby.24290","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The objective of this study was to understand the perceptions of and drivers/barriers to antiobesity medication (AOM) use among people with obesity (PwO) and health care providers (HCPs) in the United States.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In 2022, PwO and HCPs completed cross-sectional surveys that included questions on perceptions of obesity management and AOMs. Data were analyzed using descriptive statistics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Survey participants (1007 PwO and 474 HCPs) emphasized the effectiveness of lifestyle change and the patient's responsibility to address obesity. PwO reported a willingness to take newly approved AOMs long term. HCPs believed that their patients would adhere to AOMs long term if they experienced success. Both PwO and HCPs perceived an increased effectiveness of a multimodal approach to combining AOMs with HCP-guided lifestyle intervention. Potential barriers to long-term use of AOMs for both groups included concerns regarding long-term side effects and outcomes, costs and insurance coverage, and perception of AOMs that do not align with treatment of a chronic disease.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>PwO and HCPs are interested in new AOM options, but educational gaps remain as a barrier to recommended multimodal chronic care. Ongoing education that includes the known effectiveness and safety data of newer AOMs and pending outcome trials could improve shared decision-making in obesity care.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 6","pages":"1076-1086"},"PeriodicalIF":4.2,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24290","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144029965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scarce and unpredictable, yet obesogenic: modeling the impact of food insecurity on adiposity in mice","authors":"Alessandro Bartolomucci,&nbsp;John R. Speakman","doi":"10.1002/oby.24295","DOIUrl":"10.1002/oby.24295","url":null,"abstract":"","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 6","pages":"1022-1024"},"PeriodicalIF":4.2,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of metabolic phenotype changes on the development of chronic kidney disease: Panasonic cohort study 17","authors":"Junya Hironaka,&nbsp;Hiroshi Okada,&nbsp;Tetsuro Kusaba,&nbsp;Hanako Nakajima,&nbsp;Emi Ushigome,&nbsp;Masahide Hamaguchi,&nbsp;Kazushiro Kurogi,&nbsp;Hiroaki Murata,&nbsp;Naoki Yoshida,&nbsp;Masato Ito,&nbsp;Michiaki Fukui","doi":"10.1002/oby.24293","DOIUrl":"10.1002/oby.24293","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study investigated how changes in metabolic phenotype, defined by obesity and metabolic health, impact chronic kidney disease (CKD) development in a large cohort.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective cohort study analyzed health data collected between 2011 and 2021 from 84,729 Panasonic Holdings Corporation (formerly Panasonic Corporation) employees aged ≥40 years. Metabolic phenotypes were classified as metabolically healthy with no obesity (MHNO), metabolically healthy with obesity (MHO), metabolic abnormalities with no obesity (MANO), and metabolic abnormalities with obesity (MAO). Changes in metabolic phenotype over 3 years and their association with CKD development were assessed using Cox proportional hazards models adjusted for confounding variables.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>During a mean follow-up of 5.1 years, a total of 12,172 of participants (14.4%) developed CKD. Transitioning from MHO to MHNO and from MAO to MANO did not reduce CKD risk compared to each stable group. In contrast, participants in the MANO-to-MHNO and MAO-to-MHO groups significantly lowered CKD risk relative to each stable group, with hazard ratios of 0.86 (95% CI: 0.77–0.96) and 0.83 (95% CI: 0.67–1.02), respectively. The same results were observed when a rapid decline in renal function was used as the outcome.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The improvement of metabolic profile might outweigh weight reduction in CKD risk.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 6","pages":"1176-1183"},"PeriodicalIF":4.2,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid response to behavioral/pharmacological obesity treatments for binge-eating disorder predicts better clinical outcomes","authors":"Janet A. Lydecker,&nbsp;Ralitza Gueorguieva,&nbsp;Carlos M. Grilo","doi":"10.1002/oby.24292","DOIUrl":"10.1002/oby.24292","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The objective of this study was to examine rapid response and its prognostic significance in participants with binge-eating disorder (BED) and obesity in a randomized clinical trial testing behavioral and pharmacological obesity treatments for BED.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 136 participants were randomly assigned (balanced 2 × 2 factorial) to 16-week behavioral and/or pharmacological (naltrexone/bupropion) obesity interventions. Masked assessments occurred monthly throughout treatment and at posttreatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Rapid response (≥65% reduction in frequency of binge-eating episodes after 1 month of treatment), observed in 55% (<i>n</i> = 75/136) of participants, was unrelated to baseline sociodemographic and clinical characteristics. Rapid response was more common in behavioral therapy than not and in naltrexone/bupropion than placebo. Rapid response was associated with binge-eating remission. Mixed models revealed that rapid response was associated with greater reductions in binge-eating frequency, eating-disorder psychopathology, percent weight loss, and metabolic variables (total cholesterol, glycated hemoglobin A1c) at posttreatment. Rapid response effects on outcomes did not vary by treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In a randomized clinical trial testing behavioral and pharmacological obesity treatments for BED with co-occurring obesity, rapid response was a robust prognostic indicator of binge-eating remission and significantly better behavioral, psychological, and metabolic outcomes. Non-rapid response to behavioral and pharmacological obesity treatments could signal a need to switch to alternative treatments.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 6","pages":"1067-1075"},"PeriodicalIF":4.2,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144049307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}